Lorenz K J, Maier H
Abteilung für Hals-Nasen-Ohren-Heilkunde, Kopf-Hals-Chirurgie, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081 Ulm.
HNO. 2008 Apr;56(4):402-9. doi: 10.1007/s00106-007-1573-1.
Photodynamic therapy (PDT) is a relatively new method of treating superficial tumours of the skin or mucous membranes. After the injection of a photosensitiser, the tumour area is exposed to non-thermal laser light. This causes a phototoxic reaction, producing oxygen radicals that destroy the tumour cells.
From November 2004 to February 2006, a total of 24 patients with recurrent or secondary tumours after squamous cell carcinoma of the head and neck were treated with PDT at the German Armed Forces Hospital in Ulm after other treatment options had failed. Meta-tetrahydroxyphenyl chlorin (mTHPC), known under the trade name of Foscan, was used as the photosensitising agent.
Complete remission was observed in 12 patients (50%) and partial remission was seen in nine (37.5%). Three patients did not respond to treatment. The mean duration of overall survival was 305.7 days (+/-199.4) after completion of treatment. The mean duration of recurrence-free survival was 302.7 days (+/-144.9) for patients with complete remission. There were no serious complications.
Photodynamic therapy is an important treatment option for patients who develop recurrent or secondary tumours after squamous cell carcinoma of the upper aerodigestive tract and fail to respond to other treatments. In addition, PDT may play a role in the primary treatment of superficial tumours of the oral cavity, pharynx and larynx in the future.
光动力疗法(PDT)是一种治疗皮肤或黏膜浅表肿瘤的相对较新的方法。注射光敏剂后,肿瘤区域暴露于非热激光下。这会引发光毒性反应,产生氧自由基来破坏肿瘤细胞。
2004年11月至2006年2月,共有24例头颈部鳞状细胞癌复发或继发肿瘤的患者,在其他治疗方案失败后,于乌尔姆的德国武装部队医院接受了光动力疗法治疗。以商品名Foscan为人所知的间四羟基苯基氯卟啉(mTHPC)被用作光敏剂。
12例患者(50%)观察到完全缓解,9例(37.5%)出现部分缓解。3例患者对治疗无反应。治疗完成后,总生存的平均持续时间为305.7天(±199.4)。完全缓解患者的无复发生存平均持续时间为302.7天(±144.9)。未出现严重并发症。
光动力疗法对于上呼吸道消化道鳞状细胞癌后出现复发或继发肿瘤且对其他治疗无反应的患者是一种重要的治疗选择。此外,光动力疗法未来可能在口腔、咽和喉浅表肿瘤的初始治疗中发挥作用。